160 related articles for article (PubMed ID: 37339711)
1. Effective inhibition of HCoV-OC43 and SARS-CoV-2 by phytochemicals in vitro and in vivo.
Ojha D; Jessop F; Bosio CM; Peterson KE
Int J Antimicrob Agents; 2023 Sep; 62(3):106893. PubMed ID: 37339711
[TBL] [Abstract][Full Text] [Related]
2. Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2.
Schirtzinger EE; Kim Y; Davis AS
J Virol Methods; 2022 Jan; 299():114317. PubMed ID: 34634321
[TBL] [Abstract][Full Text] [Related]
3. High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.
Shen L; Niu J; Wang C; Huang B; Wang W; Zhu N; Deng Y; Wang H; Ye F; Cen S; Tan W
J Virol; 2019 Jun; 93(12):. PubMed ID: 30918074
[TBL] [Abstract][Full Text] [Related]
4. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
5. Broad antiviral and anti-inflammatory activity of Qingwenjiere mixture against SARS-CoV-2 and other human coronavirus infections.
Xie P; Fang Y; Shen Z; Shao Y; Ma Q; Yang Z; Zhao J; Li H; Li R; Dong S; Wen W; Xia X
Phytomedicine; 2021 Dec; 93():153808. PubMed ID: 34753027
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of human coronavirus OC43 and SARS-COV-2 in children with respiratory tract infection during the COVID-19 pandemic.
Keshavarz Valian N; Pourakbari B; Asna Ashari K; Hosseinpour Sadeghi R; Mahmoudi S
J Med Virol; 2022 Apr; 94(4):1450-1456. PubMed ID: 34786736
[TBL] [Abstract][Full Text] [Related]
7. Activation of STING Signaling Pathway Effectively Blocks Human Coronavirus Infection.
Liu W; Reyes HM; Yang JF; Li Y; Stewart KM; Basil MC; Lin SM; Katzen J; Morrisey EE; Weiss SR; You J
J Virol; 2021 May; 95(12):. PubMed ID: 33789998
[TBL] [Abstract][Full Text] [Related]
8. Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin.
Yang CW; Hsu HY; Lee YZ; Jan JT; Chang SY; Lin YL; Yang RB; Chao TL; Liang JJ; Lin SJ; Liao CC; Chang CS; Sytwu HK; Hung MS; Chen CT; Lee SJ
Biochem Pharmacol; 2023 Sep; 215():115688. PubMed ID: 37481137
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Interaction Between Spike Protein and Nucleocapsid Protein for Suppression and Detection of Human Coronavirus OC43.
Kim J; Kim M; Kim D; Park S; Kang M; Baek K; Choi JK; Maharjan S; Akauliya M; Lee Y; Kwon HJ
Front Immunol; 2022; 13():835333. PubMed ID: 35359936
[TBL] [Abstract][Full Text] [Related]
10. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480
[TBL] [Abstract][Full Text] [Related]
11. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
Lawrenz J; Xie Q; Zech F; Weil T; Seidel A; Krnavek D; van der Hoek L; Münch J; Müller JA; Kirchhoff F
Clin Infect Dis; 2022 Aug; 75(1):e653-e661. PubMed ID: 35079775
[TBL] [Abstract][Full Text] [Related]
12. An overview on the seven pathogenic human coronaviruses.
Kesheh MM; Hosseini P; Soltani S; Zandi M
Rev Med Virol; 2022 Mar; 32(2):e2282. PubMed ID: 34339073
[TBL] [Abstract][Full Text] [Related]
13. Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4).
Kaur R; Tada T; Landau NR
mBio; 2023 Aug; 14(4):e0109023. PubMed ID: 37382452
[TBL] [Abstract][Full Text] [Related]
14. Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator.
Chen Y; Wang X; Shi H; Zou P
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632604
[TBL] [Abstract][Full Text] [Related]
15. Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation.
Dolliver SM; Kleer M; Bui-Marinos MP; Ying S; Corcoran JA; Khaperskyy DA
PLoS Pathog; 2022 Dec; 18(12):e1011041. PubMed ID: 36534661
[TBL] [Abstract][Full Text] [Related]
16. Effect of Jinzhen granule on two coronaviruses: The novel SARS-CoV-2 and the HCoV-229E and the evidences for their mechanisms of action.
Ma Q; Wang Z; Chen R; Lei B; Liu B; Jiang H; Chen Z; Cai X; Guo X; Zhou M; Huang J; Li X; Dai J; Yang Z
Phytomedicine; 2022 Jan; 95():153874. PubMed ID: 34923232
[TBL] [Abstract][Full Text] [Related]
17. Robust Evaluation of Ultraviolet-C Sensitivity for SARS-CoV-2 and Surrogate Coronaviruses.
Boegel SJ; Gabriel M; Sasges M; Petri B; D'Agostino MR; Zhang A; Ang JC; Miller MS; Meunier SM; Aucoin MG
Microbiol Spectr; 2021 Oct; 9(2):e0053721. PubMed ID: 34668746
[TBL] [Abstract][Full Text] [Related]
18. Human Coronavirus OC43 as a Low-Risk Model to Study COVID-19.
Kim MI; Lee C
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851792
[TBL] [Abstract][Full Text] [Related]
19. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
[TBL] [Abstract][Full Text] [Related]
20. Cytopathic Effect Assay and Plaque Assay to Evaluate
Hu Y; Ma C; Wang J
Bio Protoc; 2022 Feb; 12(3):e4314. PubMed ID: 35284599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
